{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:48:33Z","timestamp":1759366113161,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.eimc.2018.12.010","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T09:05:49Z","timestamp":1549875949000},"page":"38-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u00bfEs la fosfomicina una buena alternativa terap\u00e9utica para la gonorrea en nuestro medio?"],"prefix":"10.1016","volume":"38","author":[{"given":"Yuliya","family":"Zboromyrska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Guerrero-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Ben\u00edtez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2018.12.010_bib0055","unstructured":"World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO: Geneva, Switzerland, 2017 [consultado 24 Jun 2018]. Disponible en: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf."},{"key":"10.1016\/j.eimc.2018.12.010_bib0060","unstructured":"European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe, 2015. Stockholm: ECDC; 2017 [consultado 24 Jun 2018]. Disponible en: https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/gonococcal-antimicrobial-susceptibility-surveillance-Europe-2015.pdf"},{"key":"10.1016\/j.eimc.2018.12.010_bib0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eimc.2016.11.012","article-title":"Risk factors for antimicrobial-resistant Neisseria gonorrhoeae and characteristics of patients infected with gonorrhea","volume":"36","author":"Fuertes de Vega","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2018.12.010_bib0070","first-page":"7","article-title":"Future prospects for Neisseria gonorrhoeae treatment","author":"Suay-Garcia","year":"2018","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.eimc.2018.12.010_bib0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0956462412472837","article-title":"2012 European guideline on the diagnosis and treatment of gonorrhoea in adults","volume":"24","author":"Bignell","year":"2013","journal-title":"Int J STD AIDS"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2018.12.010_bib0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000222063","article-title":"Treatment of acute and subacute gonococcal urethritis with fosfomycin","volume":"23","author":"Lopez-Gracia","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.eimc.2018.12.010_bib0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cmi.2016.03.031","article-title":"Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2018.12.010_bib0090","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jac\/dkt540","article-title":"In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae","volume":"69","author":"Barbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2018.12.010_bib0095","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/AAC.04536-14","article-title":"In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates","volume":"59","author":"Hauser","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2018.12.010_bib0100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmi.2017.08.023","article-title":"High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers","volume":"24","author":"Wijma","year":"2018","journal-title":"Clin Microbiol Infect"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X19300114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X19300114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:06:04Z","timestamp":1759323964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X19300114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0213005X19300114"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2018.12.010","relation":{},"ISSN":["0213-005X"],"issn-type":[{"type":"print","value":"0213-005X"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfEs la fosfomicina una buena alternativa terap\u00e9utica para la gonorrea en nuestro medio?","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2018.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}